MBX Biosciences, Inc. (MBX) Stock

HealthcareBiotechnology Website

4 of the hedge funds AlphaScala tracks reported MBX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Marshall Wace's at $22.18M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Oct 21, 2026.

Which hedge funds own MBX?

From 13F filings
FundShares HeldPosition ValueChange vs prior Q
Marshall Wace402K$22.18M+541%
Millennium Management
Israel Englander
226K$12.48M-60%
D.E. Shaw
David Shaw
183K$10.09M-37%
Blackstone6K$305.4KNEW

13F holdings as of Jun 30, 2026

Explore all tracked funds →

Are MBX Biosciences, Inc. insiders buying or selling?

SEC Form 4 filings
90 days to Oct 21, 2026
Buys
0
Sells
1
Net $
-$24K
Unique insiders
1
DateInsiderRoleTypeSharesValue
Aug 4, 26Azoulay SalomonChief Medical OfficerSELL370$24K

SEC Form 4 filings as of Oct 21, 2026

See cluster-buy signals across all tickers →

MBX price chart

Powered by TradingView

What does MBX Biosciences, Inc. do?

Mbx Biosciences Inc. is a biopharmaceutical company focused on the research and development of innovative endocrine therapeutics. It strives to address unmet medical needs through pioneering treatments for endocrine disorders. The company's central aim is to develop precision endocrinology therapies, leveraging proprietary technologies to create treatment options that are more precise and effective for specific patient populations. Mbx Biosciences operates at the intersection of biotechnology and healthcare, significantly impacting the health sector by working towards solutions that can transform the management of hormonal disorders. In terms of market significance, Mbx Biosciences represents the advancing frontier of personalized medicine, emphasizing targeted therapies that promise improved outcomes and quality of life for patients suffering from conditions related to hormonal imbalances. By contributing to the biopharmaceutical landscape with innovative solutions, it holds a vital role in advancing both the scientific understanding and therapeutic interventions in endocrine health.

CEO
Mr. Peter Kent Hawryluk MBA
Employees
63
Ask about MBXAI research agent